Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
出版年份 2015 全文链接
标题
Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
作者
关键词
Minimal Residual Disease, Chimeric Antigen Receptor, Ibrutinib, Bispecific Antibody, Acute Lymphoid Leukemia
出版物
Journal of Hematology & Oncology
Volume 8, Issue 1, Pages -
出版商
Springer Nature
发表日期
2015-09-03
DOI
10.1186/s13045-015-0195-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
- (2015) A. Rothe et al. BLOOD
- Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies
- (2015) Britny Rogala et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Blinatumomab for the treatment of B-cell lymphoma
- (2015) Eunhye Oak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab approved for rare leukemia
- (2014) K. Traynor AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE(R)) antibody construct blinatumomab as a potential therapy
- (2014) Z. Zimmerman et al. INTERNATIONAL IMMUNOLOGY
- Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
- (2014) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies
- (2014) Caroline S Breton et al. Journal of Hematology & Oncology
- A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy
- (2014) Josée Golay et al. JOURNAL OF IMMUNOLOGY
- A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+tumor cells
- (2014) Uwe Reusch et al. mAbs
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
- (2014) G Zugmaier et al. Blood Cancer Journal
- Blinatumomab, a Bi-Specific Anti-CD19/CD3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications
- (2014) Lindsey M. Hoffman et al. Frontiers in Oncology
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
- (2013) D. T. Teachey et al. BLOOD
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
- (2013) R. Wong et al. HAEMATOLOGICA
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Novel agents and biomarkers for acute lymphoid leukemia
- (2013) Yanmin Zhao et al. Journal of Hematology & Oncology
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
- (2013) Ethan Q Han et al. Journal of Hematology & Oncology
- MEK and the inhibitors: from bench to bedside
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- B-Raf and the inhibitors: from bench to bedside
- (2013) Tiangui Huang et al. Journal of Hematology & Oncology
- Targeting p53 by small molecules in hematological malignancies
- (2013) Manujendra N Saha et al. Journal of Hematology & Oncology
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- STAT inhibitors for cancer therapy
- (2013) Muhammad Furqan et al. Journal of Hematology & Oncology
- MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells
- (2013) P. Leone et al. JNCI-Journal of the National Cancer Institute
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- Toward victory in adult ALL: blinatumomab joins in
- (2012) R. Bassan BLOOD
- Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
- (2012) M. Klinger et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- The myth of the second remission of acute leukemia in the adult
- (2012) S. J. Forman et al. BLOOD
- CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis
- (2012) Elaine Y. Chung et al. JOURNAL OF CLINICAL INVESTIGATION
- Blinatumomab: A historical perspective
- (2012) Dirk Nagorsen et al. PHARMACOLOGY & THERAPEUTICS
- SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
- (2011) V. Blanc et al. CLINICAL CANCER RESEARCH
- Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab
- (2011) Dirk Nagorsen et al. EXPERIMENTAL CELL RESEARCH
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
- (2010) R Handgretinger et al. LEUKEMIA
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
- (2009) Dirk Nagorsen et al. LEUKEMIA & LYMPHOMA
- Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells
- (2008) Sandrine d’Argouges et al. LEUKEMIA RESEARCH
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Treatment of Adult Acute Lymphoblastic Leukemia
- (2008) Nicola Gökbuget et al. SEMINARS IN HEMATOLOGY
- Germinal center structure and function: Lessons from CD19
- (2008) Robert H. Carter et al. SEMINARS IN IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation